At a glance
- Originator Pfizer
- Class Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 19 Oct 2000 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
- 23 Jun 2000 Warner-Lambert has merged with Pfizer
- 02 Feb 1996 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)